ALIGN研究设计与基线特征:阿曲生坦治疗IgA肾病的随机对照试验
ALIGN是一项3期随机双盲安慰剂对照试验,评估选择性ETA受体拮抗剂阿曲生坦在IgA肾病患者中的疗效与安全性。纳入404例患者(主 stratum 340例,SGLT2i stratum 64例),主要终点为主 stratum 第36周24小时UPCR较基线变化。基线平均eGFR 58.9 ml/min/1.73 m2,中位UPCR 1.4 g/g。
要点
- ALIGN试验纳入活检确诊IgA肾病、蛋白尿≥1 g/d、eGFR≥30 ml/min/1.73 m2且已优化RAS抑制剂治疗的高危患者。
- 阿曲生坦0.75 mg每日口服,主要终点为第36周24小时UPCR较基线变化。
- 探索性stratum评估阿曲生坦联合SGLT2i的疗效与安全性。
核心结论
- 正在进行的ALIGN试验评估阿曲生坦在优化RAS抑制剂治疗背景下仍存在疾病进展风险的全球代表性IgA肾病人群中的疗效与安全性。
研究设计与样本
- 3期随机双盲安慰剂对照临床试验(ALIGN,NCT04573478),在全球20个国家入组404例患者。
- 主stratum 340例,探索性SGLT2i stratum 64例;随机接受阿曲生坦0.75 mg或安慰剂口服每日一次,治疗132周后洗脱4周。
主要发现
- 主stratum基线平均年龄44.7岁,女性占42.4%,平均eGFR 58.9 ml/min/1.73 m2,中位UPCR 1.4 g/g。
- 主要终点为主stratum第36周24小时UPCR较基线变化;关键次要终点包括第136周eGFR较基线变化、安全性和耐受性。
关键数值与推荐
- 入选标准:活检确诊IgA肾病,总蛋白排泄≥1 g/d,eGFR≥30 ml/min/1.73 m2,接受最大耐受稳定剂量RAS抑制剂。
- 探索性stratum额外要求接受稳定剂量SGLT2i。
临床怎么用
- 该试验针对已优化RAS抑制剂治疗但仍有高进展风险的IgA肾病患者,评估阿曲生坦降低蛋白尿和保护肾功能的作用。
- 探索性stratum为阿曲生坦联合SGLT2i的联合治疗策略提供初步证据。
局限性
- 本文报告的是研究设计与基线特征,疗效和安全性结果尚未公布。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Endothelin A (ETA) receptor activation is a driver of proteinuria, kidney inflammation, and fibrosis in IgA nephropathy (IgAN). Atrasentan, a selective ETA receptor antagonist, has potential to reduce proteinuria and preserve kidney function in IgAN. ALIGN (NCT04573478) is a phase 3, randomized, double-blind, placebo-controlled clinical trial of atrasentan in patients with IgAN at high risk of kidney function loss. METHODS: Eligibility criteria for the ALIGN main stratum included patients with biopsy-proven IgAN, total protein excretion ≥ 1 g/d, estimated glomerular filtration rate (eGFR) ≥ 30 ml/min per 1.73 m2, receiving a maximally tolerated stable dose of a renin-angiotensin system (RAS) inhibitor. An exploratory stratum enrolled participants also receiving a stable dose of sodium glucose cotransporter-2 inhibitors (SGLT2i). Participants were randomized to 0.75 mg atrasentan or placebo orally daily for 132 weeks followed by a 4-week wash-out period. The primary outcome is proteinuria change from baseline (24-hour urine protein-to-creatinine ratio [UPCR]) to week 36 in the main stratum. Key secondary end points include eGFR change from baseline to week 136, safety, and tolerability. RESULTS: Enrolment occurred across 20 countries; 404 patients were randomized: 340 in the main stratum and 64 in the SGLT2i stratum. At baseline in the main stratum, mean age was 44.7 years, 42.4% were female, mean eGFR and median UPCR were 58.9 ml/min per 1.73 m2 and 1.4 g/g, respectively. CONCLUSION: The ongoing ALIGN trial evaluates the efficacy and safety of atrasentan in a representative global IgAN population at risk for disease progression despite optimized RAS inhibitor therapy and includes an exploratory stratum evaluating atrasentan use in combination with an SGLT2i.
引用
- Heerspink HJL, Jardine M, Kohan DE, et al. Study Design and Baseline Characteristics of ALIGN, a Randomized Controlled Study of Atrasentan in Patients With IgA Nephropathy. Kidney Int Rep. 2024. PMID: 39810771. doi:10.1016/j.ekir.2024.10.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。